Regorafenib (CT) (NCT07071961)

Name: Regorafenib (CT) trial for Colorectal Cancer (NCT07071961)
Uploaded: 2026-10-31T16:43:57.262Z
Duration: 1 min 19 s
Description: Regorafenib (CT) trial for Colorectal Cancer (NCT07071961). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT07071961.

Regorafenib (Reg) and Lorigerlimab (Lor), RELO Regimen, in Treatment of High-risk Patients With Colorectal Cancer With Radiographic Occult Molecular Residual Disease After End of Established Definitive Therapy [ReLOAD Trial]: a one-minute explainerNCT070719611 min

Regorafenib (CT) trial for Colorectal Cancer (NCT07071961). This is a short film with English narration. The transcript is on this page, and the written brief is separate.

What the film says

Read the transcript

This trial is for adults after complete removal of stage II, III, or IV colorectal cancer and completion of planned adjuvant treatment. Scans show no cancer, but blood tests still detect tumor DNA.

The idea: oral regorafenib blocks tumor-growth and blood-vessel signals; intravenous lorigerlimab blocks PD-1 and CTLA-4 immune brakes. Treatment lasts up to six months. Researchers assess tumor-DNA clearance and safety. A Signatera test must confirm residual disease before treatment.

This phase 2 study plans 16 patients. Kanwal Raghav leads at MD Anderson in Houston, the sole recruiting US site.

Public record; not medical advice.

Read the full brief →

Already in a trial?

It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.

Organize my trial

7-day free trial, then $9 a month. Cancel anytime.